Administration of a Second Dose of the Moderna COVID-19 Vaccine After an Immediate Hypersensitivity Reaction With the First Dose: Two Case Reports | Annals of Internal Medicine
Background: In December 2020, the U.S. Food and Drug Administration issued an emergency use authorization for the Pfizer-BioNTech and Moderna messenger RNA vaccines for the prevention of COVID-19. This authorization was a significant step toward mitigating the burden of the disease. Nevertheless, hypersensitivity reactions to these vaccines are being reported (5.0 and 2.8 cases per million doses…
